## Abstract ## Purpose: To compare enhancement of liver parenchyma in MR imaging after injection of hepatocyte‐specific contrast media. ## Materials and Methods: Patients (n = 295) with known/suspected focal liver lesions randomly received 0.025 mmol gadoxetic acid/kg body weight or 0.05 mmol ga
Gadobenate dimeglumine as a contrast agent for MRI of the mouse liver
✍ Scribed by Yusuke Inoue; Kohki Yoshikawa; Yukihiro Nomura; Kiyoko Izawa; Morio Shimada; Arinobu Tojo; Kuni Ohtomo
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 180 KB
- Volume
- 20
- Category
- Article
- ISSN
- 0952-3480
- DOI
- 10.1002/nbm.1135
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ## Purpose To compare gadobenate dimeglumine (Gd‐BOPTA)–enhanced MR angiography (i.e., contrast‐enhanced MRA [CE‐MRA]) of the pedal vasculature with selective digital subtraction angiography (DSA) in patients with peripheral arterial occlusive disease (PAOD). ## Materials and Methods
## Abstract We have previously shown that the concentration of Gd‐DTPA as, a function of time ([Gd‐DTPA]__~t~__(__t__)) in the myocardium following an intravenous bolus injection of Gd‐DTPA can be moldered using the Modified Kety Equation. Fitting this model to measurements of [Gd‐DTPA]__~t~__(__t_
## Abstract This work demonstrates that intraventricular microinjections of a low dose of potassium dichromate (0.4 μL of 10 mM solution) yield a specific contrast enhancement of white matter (WM) tracts in __T__~1~‐weighted 3D MRI of mouse brain in vivo. Pronounced and persistent signal increases
## Abstract From May 2007 to January 2008, patients with Stage 3‐5 chronic kidney disease (CKD) undergoing gadobenate dimeglumine (GBD)‐enhanced magnetic resonance (MR) examinations were included in the retrospective investigation. The electronic medical records were reviewed to assess the prevalen